SG11201609014TA - Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy - Google Patents
Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapyInfo
- Publication number
- SG11201609014TA SG11201609014TA SG11201609014TA SG11201609014TA SG11201609014TA SG 11201609014T A SG11201609014T A SG 11201609014TA SG 11201609014T A SG11201609014T A SG 11201609014TA SG 11201609014T A SG11201609014T A SG 11201609014TA SG 11201609014T A SG11201609014T A SG 11201609014TA
- Authority
- SG
- Singapore
- Prior art keywords
- gpc3
- targeting drug
- administered
- patient responsive
- drug therapy
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461990238P | 2014-05-08 | 2014-05-08 | |
PCT/JP2015/002352 WO2015170480A1 (en) | 2014-05-08 | 2015-05-08 | Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201609014TA true SG11201609014TA (en) | 2016-12-29 |
Family
ID=54392336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201609014TA SG11201609014TA (en) | 2014-05-08 | 2015-05-08 | Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
Country Status (9)
Country | Link |
---|---|
US (1) | US11760807B2 (en) |
EP (1) | EP3141603A4 (en) |
JP (1) | JP6827319B2 (en) |
KR (1) | KR102409014B1 (en) |
CN (2) | CN113933504A (en) |
AR (1) | AR100353A1 (en) |
SG (1) | SG11201609014TA (en) |
TW (1) | TWI735410B (en) |
WO (1) | WO2015170480A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
US11376326B2 (en) | 2015-07-01 | 2022-07-05 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective |
US10377833B2 (en) * | 2016-07-22 | 2019-08-13 | Beijing Mabworks Biotech Co., Ltd. | Bispecific anti-HER2 antibody |
CN106591371A (en) * | 2016-11-25 | 2017-04-26 | 哈尔滨百伊生生物科技有限公司 | CD16A/GPC3 double-antibody lentivirus expression vector, and construction method and application thereof |
JP7264329B2 (en) | 2017-05-17 | 2023-04-25 | シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) | Generation of a Synthetic Promoter (SYN+PRO) Inducible by Activation of Mammalian T Cells to Improve T Cell Therapy |
CN107129536A (en) * | 2017-05-24 | 2017-09-05 | 广州市拜沃思生物科技有限公司 | A kind of bispecific antibody and its preparation method and application |
CN109385403B (en) * | 2017-08-04 | 2024-03-08 | 恺兴生命科技(上海)有限公司 | GPC 3-targeting CAR NK cells |
US20200216542A1 (en) | 2017-09-20 | 2020-07-09 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
AR114112A1 (en) * | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | GLIPICAN 3 ANTIBODIES AND CONJUGATES THEREOF |
WO2020066043A1 (en) * | 2018-09-28 | 2020-04-02 | オリンパス株式会社 | Microscope system, projection unit, and image projection method |
CN113811315A (en) * | 2019-01-18 | 2021-12-17 | 育世博生物科技股份有限公司 | Novel CD16 positive natural killer cell and method for culturing CD16 positive natural killer cell |
CN110954385B (en) * | 2019-12-17 | 2021-05-25 | 李惠 | Pathological tissue dehydration instrument |
CN113214406B (en) * | 2020-01-21 | 2022-08-02 | 苏州普乐康医药科技有限公司 | Preparation method and application of fusion protein combined with GPC3 |
JP2023552290A (en) * | 2020-11-19 | 2023-12-15 | アーディアジェン コーポレーション | GPC3 binding agents, conjugates thereof and methods of use thereof |
WO2022171100A1 (en) * | 2021-02-10 | 2022-08-18 | 江苏先声药业有限公司 | Humanized gpc3 antibody and application thereof |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5322678A (en) | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
US6617156B1 (en) | 1997-08-15 | 2003-09-09 | Lynn A. Doucette-Stamm | Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
PT1071700E (en) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
ES2694002T3 (en) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polypeptide comprising an Fc region of variant human IgG1 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
DK1156823T3 (en) | 1999-02-12 | 2009-01-19 | Scripps Research Inst | Methods for treating tumors and metastases using a combination of anti-angiogenic therapies and immunotherapies |
PT1914244E (en) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Method of modulating the activity of functional immune molecules |
CA2785941C (en) | 2000-10-06 | 2017-01-10 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
US6436411B1 (en) | 2000-10-23 | 2002-08-20 | The Center For The Improvement Of Human Functioning, Int'l., Inc. | Cancer treatment method |
WO2002040545A2 (en) | 2000-11-17 | 2002-05-23 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point |
WO2002079255A1 (en) | 2001-04-02 | 2002-10-10 | Idec Pharmaceuticals Corporation | RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII |
JP4281869B2 (en) | 2001-06-22 | 2009-06-17 | 中外製薬株式会社 | Cell growth inhibitor containing anti-glypican 3 antibody |
EP3960855A1 (en) | 2001-12-28 | 2022-03-02 | Chugai Seiyaku Kabushiki Kaisha | Method for stabilizing proteins |
AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
WO2003100429A2 (en) | 2002-05-23 | 2003-12-04 | Sunnybrook And Women's College Health Sciences Centre | Diagnosis of hepatocellular carcinoma |
AU2002328429A1 (en) | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE |
AU2002338020A1 (en) | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | Antibody against blood-solubilized n-terminal peptide in gpc3 |
WO2004023145A1 (en) | 2002-09-04 | 2004-03-18 | Perseus Proteomics Inc. | Method of diagnosing cancer by detecting gpc3 |
DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
NZ541503A (en) | 2003-01-22 | 2008-09-26 | Glycart Biotechnology Ag | Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
WO2005023301A1 (en) | 2003-09-04 | 2005-03-17 | Chugai Seiyaku Kabushiki Kaisha | Remedy and detection drug for bile duct cancer |
US20080089892A1 (en) | 2004-01-12 | 2008-04-17 | Eli Lilly And Co. | Fc Region Variants |
JP4658926B2 (en) | 2004-04-28 | 2011-03-23 | 株式会社ペルセウスプロテオミクス | Predictive drug for recurrence after liver cancer treatment |
JP4331227B2 (en) | 2004-07-09 | 2009-09-16 | 中外製薬株式会社 | Anti-glypican 3 antibody |
NZ579543A (en) | 2004-07-09 | 2011-07-29 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody |
DK1776384T3 (en) | 2004-08-04 | 2013-09-02 | Mentrik Biotech Llc | VARIANT Fc REGIONS |
CA2577370A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
KR20070057839A (en) | 2004-08-19 | 2007-06-07 | 제넨테크, 인크. | Polypeptide variants with altered effector function |
KR20130103580A (en) * | 2004-08-24 | 2013-09-23 | 추가이 세이야쿠 가부시키가이샤 | Adjuvant therapy with the use of anti-glypican 3 antibody |
WO2006038588A1 (en) | 2004-10-05 | 2006-04-13 | Perseus Proteomics Inc. | Drug for monitoring worsening of hepatitis |
NZ554940A (en) | 2004-10-26 | 2010-04-30 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody having modified sugar chain |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
JPWO2006067847A1 (en) | 2004-12-22 | 2008-06-12 | 中外製薬株式会社 | Antibody production method using cells in which fucose transporter function is inhibited |
AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
CA2614181A1 (en) | 2005-07-01 | 2007-01-11 | Medimmune, Inc. | An integrated approach for generating multidomain protein therapeutics |
DK1919503T3 (en) | 2005-08-10 | 2014-12-15 | Macrogenics Inc | Identification and preparation of antibodies with variant fc regions and methods of use thereof |
JP2007093274A (en) | 2005-09-27 | 2007-04-12 | Perseus Proteomics Inc | Diagnostic method for cancer and therapeutic agent therefor |
EP1931709B1 (en) | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
WO2007059782A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
WO2007103470A2 (en) * | 2006-03-06 | 2007-09-13 | Medimmune, Inc. | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
WO2007137170A2 (en) | 2006-05-20 | 2007-11-29 | Seattle Genetics, Inc. | Anti-glypican-3 antibody drug conjugates |
ATE501436T1 (en) * | 2006-09-13 | 2011-03-15 | Glycode | METHOD FOR STUDYING THE RESPONSE TO TREATMENT WITH A MONOCLONAL ANTIBODY |
EP2174938A1 (en) | 2006-10-12 | 2010-04-14 | SuperGen, Inc. | Quinoline derivatives for modulating DNA methylation |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
EP3689912A1 (en) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
BRPI0817637A2 (en) | 2007-09-28 | 2015-09-08 | Chugai Pharmaceutical Co Ltd | anti-glipican-3 antibody having improved plasma kinetics |
ES2532461T3 (en) | 2007-12-26 | 2015-03-27 | Xencor, Inc. | FC variants with altered FCRN binding |
US8663929B2 (en) | 2008-03-17 | 2014-03-04 | University Of Miyazaki | Method for detection of liver cancer cell using anti-glypican-3 antibody |
CL2009000647A1 (en) | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent for attenuating a side effect comprising said antibody; method of treating or preventing liver cancer of a subject. |
CN101377506A (en) | 2008-04-16 | 2009-03-04 | 北京科美东雅生物技术有限公司 | Monophosphoinositide proteoglycans-3 chemiluminescence immune analysis determination reagent kit and preparing method thereof |
US8541178B2 (en) | 2008-05-13 | 2013-09-24 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
EP2420515A4 (en) | 2009-04-16 | 2013-08-28 | Univ Tokyo | Diagnosis and treatment of cancer using anti-tmprss11e antibody |
EP2496690A4 (en) | 2009-11-05 | 2013-07-24 | Sloan Kettering Inst Cancer | Catenae: serosal cancer stem cells |
CN102276721B (en) | 2010-06-12 | 2013-12-25 | 上海市肿瘤研究所 | Monoclonal antibody for serological diagnosis of liver cancer and application thereof |
SG190727A1 (en) | 2010-11-30 | 2013-07-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
EP3070104B1 (en) | 2011-04-19 | 2017-12-27 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
CN113480639A (en) | 2012-02-09 | 2021-10-08 | 中外制药株式会社 | Fc region variants of antibodies |
BR112014018374A8 (en) | 2012-03-02 | 2017-07-11 | Roche Glycart Ag | METHOD FOR PREDICTING THE RESPONSE OF A PATIENT WITH CANCER, KIT, ANTIBODY, METHOD FOR THE TREATMENT OF CANCER AND PHARMACEUTICAL COMPOSITION |
JP6494507B2 (en) | 2012-06-01 | 2019-04-03 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | High affinity monoclonal antibody against glypican-3 and use thereof |
EP2863224A4 (en) | 2012-06-18 | 2016-05-04 | Nat Cancer Ct | Kit for diagnosing malignant melanoma |
TWI693073B (en) * | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | Therapeutic agent for GPC3 target is the effective therapeutic agent for GPC3 target administered to patients |
CN107460201A (en) | 2013-05-08 | 2017-12-12 | 科济生物医药(上海)有限公司 | Encode the nucleic acid of the Chimeric antigen receptor albumen of GPC 3 and express the T lymphocytes of the Chimeric antigen receptor albumen of GPC 3 |
-
2015
- 2015-05-08 EP EP15789676.2A patent/EP3141603A4/en active Pending
- 2015-05-08 TW TW104114756A patent/TWI735410B/en active
- 2015-05-08 JP JP2016517818A patent/JP6827319B2/en active Active
- 2015-05-08 CN CN202111206881.9A patent/CN113933504A/en active Pending
- 2015-05-08 AR ARP150101411A patent/AR100353A1/en unknown
- 2015-05-08 WO PCT/JP2015/002352 patent/WO2015170480A1/en active Application Filing
- 2015-05-08 KR KR1020167034321A patent/KR102409014B1/en active IP Right Grant
- 2015-05-08 US US15/309,391 patent/US11760807B2/en active Active
- 2015-05-08 SG SG11201609014TA patent/SG11201609014TA/en unknown
- 2015-05-08 CN CN201580024198.XA patent/CN106459959A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AR100353A1 (en) | 2016-09-28 |
EP3141603A1 (en) | 2017-03-15 |
JP6827319B2 (en) | 2021-02-10 |
WO2015170480A1 (en) | 2015-11-12 |
US20170073426A1 (en) | 2017-03-16 |
CN106459959A (en) | 2017-02-22 |
TW201625949A (en) | 2016-07-16 |
US11760807B2 (en) | 2023-09-19 |
KR20170003972A (en) | 2017-01-10 |
TWI735410B (en) | 2021-08-11 |
KR102409014B1 (en) | 2022-06-14 |
EP3141603A4 (en) | 2017-12-27 |
CN113933504A (en) | 2022-01-14 |
JPWO2015170480A1 (en) | 2017-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201609014TA (en) | Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy | |
IL239488B (en) | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy | |
PT3212233T (en) | Combination therapy for treatment of disease | |
EP3210604C0 (en) | Uses of duloxetine hcl medicament in preparing pharmaceutical composition for treatment of cancer | |
IL254746A0 (en) | System and method for controlling the administration of a drug to a patient | |
HK1258128A1 (en) | Selection of patients for combination therapy | |
ZA201900921B (en) | Administration of substances to animals | |
HK1243659A1 (en) | Integration of glucose data to adjust inhaled insulin dose | |
HK1256875A1 (en) | Enhanced delivery of drugs to the brain | |
IL253141B (en) | Products for the delivery of therapeutic/diagnostic compounds to the heart | |
IL252649A0 (en) | Devices for delivering non-invasive neuromodulation to a patient | |
IL249502B (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies | |
HK1243364A1 (en) | Device for facilitating the administration of a medicament to the lung by a catheter | |
GB201403996D0 (en) | Traditional chinese medicine composition for the treatment of diabetes | |
EP2946777C0 (en) | Medicine for treatment of neuropathic disease | |
EP3305347A4 (en) | Fluid infusion apparatus used for administering medicament to patient | |
HUE056624T2 (en) | Pharmaceutical preparation of carbohydrates for therapeutic use | |
GB201412842D0 (en) | Catheter for the delivery of therapeutic fluid | |
PT3143032T (en) | Novel derivatives of oxazaphosphorines and therapeutic uses thereof | |
HK1225969A1 (en) | Treatment of crohn's disease using low doses of laquinimod | |
IL252080A0 (en) | Oral administration of unstable or poorly-absorbed drugs | |
IL248252A0 (en) | Drug for treatment of tinnitus patients | |
IL248253A0 (en) | Drug for treatment of tinnitus patients | |
GB201522942D0 (en) | A kind of traditional chinese medicine combination for the treatment of vertigo | |
ZA201408372B (en) | Therapeutic biologic for treatment of hepatocellular carcinoma |